ClinicalTrials.gg
CompletedNCT03642821INSTANTUpdated Sep 18, 2025

Intracranial Aneurysms Treatment With the OPTIMA Coil System

An observational study in Intracranial Aneurysm and Coiling Therapy, sponsored by Balt Extrusion. Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Balt Extrusion · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.

Enrollment
18th of 43
300 · median 206
Started
2019
with 4 others
Observational
43 of 66
10 open now
Registered
35th of 66
by date
Lead sponsor
3 of 66
Balt Extrusion

Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 18th largest by enrollment of the 43 observational ones that give a count, is one of 5 that started in 2019, is one of 43 observational ones, and was the 35th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Intracranial Aneurysm with a site in France, or all of them as a file.
02

Study summary

International, non-randomized, European , multicenter, observational study to collect data for the treatment of intracranial aneurysms with OPTIMA coils system to further document its safety and efficacy

03

Conditions studied

  • Intracranial Aneurysm
  • Coiling Therapy

Keywords

  • coil
  • aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. giant aneurysms (>25 mm)
  2. recanalized aneurysms initially treated with stent or flow diverter (Only aneurysms initially treated with coils are eligible)
  3. aneurysm treated with parent artery occlusion
  4. dissecting or fusiform aneurysms
  5. aneurysms associated with an arteriovenous malformation
  6. aneurysm intended to be treated with flow diverter or flow disrupter during the procedure
  7. aneurysm intended to be treated in a staged procedure
  8. intracranial tumor (except meningioma)
  9. Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up, as requested according to sites current practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with small or large intracranial aneurysm, ruptured or unruptured, intended to be selectively treated with the OPTIMA coil system. Patients with recanalized aneurysms previously treated with coils exclusively are also eligible. Balloon and stent assisted coiling are allowed at index procedure.
  2. In case of multiple aneurysms, patient can be included when only 1 aneurysm is treated during the procedure and none of the other aneurysms are treated up to 30 days post-procedure
  3. Patient older than 18 years
  4. Patient who has been informed of the study and has signed an form where applicable according to local regulations.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • Deviceintracranial aneurysm coiling

    endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system

    Also known as: OPTIMA coils

06

What researchers measure

Primary outcomes

  1. Morbi-mortality at 30 days

    Rate of adverse events including thromboembolic events, the bleeding/rebleeding episodes, the rate of retreated aneurysm and the rate of mortality occurring during the procedure and up to 30 days.

    Time frame: 30 days

  2. Clinical outcomes (mRS) at 30 days

    Classification of the patient clinical and neurological outcomes based on modified Rankin Scale from 0 (no symptoms a all) to 6 (dead). Global outcomes of mRS 0-2 are considered good and those of mRS 3-6 (including mRS 6 - deceased) are considered to be poor.

    Time frame: 30 days

Secondary outcomes

  1. Morbi-mortality at 12 months

    Rate of adverse events including thromboembolic events, the bleeding/rebleeding episodes, the rate of retreated aneurysm and the rate of mortality occurring within 12 months after the procedure.

    Time frame: 12 months

  2. Clinical outcomes (mRS) at 12 months

    Classification of the patient clinical and neurological outcomes based on modified Rankin Scale from 0 (no symptoms a all) to 6 (dead). Global outcomes of mRS 0-2 are considered good and those of mRS 3-6 (including mRS 6 - deceased) are considered to be poor.

    Time frame: 12 months

  3. Aneurysm occlusion rate

    Post-procedure and 12-month follow-up efficacy based on the assessment of the aneurysm occlusion rate according to the 3-grade Montreal scale (complete occlusion/neck remnant/aneurysm remnant).

    Time frame: Up to 24h and 12 months

07

Study locations

20 sites
  • Medizinische Universität Innsbruck
    Innsbruck, A-6020, Austria
  • CHU de Bordeaux - Hôpital Pellegrin
    Bordeaux, 33000, France
  • CHU de Brest - Hôpital La Cavale Blanche
    Brest, 29200, France
  • Hospices Civils de Lyon - Hôpital Neurologique
    Bron, 69677, France
  • CHU Côte de Nâcre
    Caen, 14000, France
  • Hôpital Privé Clairval
    Marseille, 13009, France
  • CHU Gui de Chaulliac
    Montpellier, Costalat, France
  • CHU Hôpital Maison Blanche
    Reims, 51000, France
  • CHU Charles-Nicolle
    Rouen, 76000, France
  • CHRU Strasbourg Hautepierre
    Strasbourg, 67200, France
  • Zentralklinikum Augsburg
    Augsburg, 86156, Germany
  • Azienda Ospedallera
    Catania, 95126, Italy
  • San Gerardo Hospital
    Monza, 20900, Italy
  • Antonio Cardarelli Hospital
    Naples, 80131, Italy
  • ULSS8 Berica Ospedale San Bortolo
    Vicenza, 36100, Italy
  • University of Latvia, Faculty of Medicine
    Riga, Latvia
  • Hospital Universitario de Burgos
    Burgos, 09006, Spain
  • Hospital: Fundacion Jimenez Diaz
    Madrid, 28222, Spain
  • Hospital: Puerta de Hierro
    Madrid, 28222, Spain
  • HUG Hôpital cantonal universitaire de geneva
    Geneva, CH-1211, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2021, 31 months.

Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2018
First posted
Aug 22, 2018
StartActual
Mar 1, 2019
Primary completionActual
Oct 13, 2021
CompletionActual
Feb 15, 2023
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03642821
Lead sponsor
Balt Extrusion
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Mar 1, 2019
Primary completion
Oct 13, 2021
Completion
Feb 15, 2023
Last update
Sep 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion